Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPraxis NDA review for relutrigine extended 3 months to Dec 27; no new studies required
Filed June 29, 2026 · Period ending June 29, 2026 · ~1 min read
Key Changes
-
high
FDA pushed relutrigine NDA decision date from Sept 27 to Dec 27, 2026, delaying potential commercialization for rare pediatric epilepsies by three months.
Item 8.01 verify on EDGAR → -
high
FDA cited no safety or manufacturing concerns and requested no new clinical studies, suggesting core data package and product quality are acceptable.
Item 8.01 verify on EDGAR → -
medium
Extension triggered by Praxis submitting additional sensitivity analyses of existing trial data, which FDA classified as a major amendment requiring extra review time.
Item 8.01 verify on EDGAR →
Summary
Praxis disclosed that the FDA extended its review of the relutrigine NDA by three months, moving the target decision date from September 27 to December 27, 2026. The delay follows Praxis's submission of additional statistical analyses of existing clinical data, which the FDA deemed a major amendment warranting extra review time.
Importantly, the FDA requested no new clinical studies and raised no safety or manufacturing concerns, indicating the core application appears sound. For investors, this is a procedural delay rather than a substantive setback.
The three-month extension postpones potential revenue from relutrigine for SCN2A and SCN8A epilepsies, but the absence of safety flags or requests for new trials suggests the approval pathway remains intact. The company's decision to submit supplemental analyses may reflect proactive efforts to strengthen the application's statistical case. The updated December timeline now becomes the key catalyst to watch.
Section-by-Section Diff
Event · Item 8.01 — Other Events
FDA extended relutrigine NDA review by 3 months to Dec 27, 2026 due to major amendment; no new studies or safety concerns cited.
Added in current filing · verify on EDGAR →
the U.S. Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application (“NDA”) for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”), setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026.
The FDA has pushed back the target decision date for Praxis's relutrigine drug application from September 27, 2026 to December 27, 2026, a three-month delay. This extends the timeline before the company can potentially commercialize relutrigine for rare pediatric epilepsies.
Added in current filing · verify on EDGAR →
The extension follows the Company’s submission of additional sensitivity analyses of existing clinical data, which the FDA has deemed a “major amendment,” allowing additional time for the FDA to review.
The delay stems from Praxis submitting extra statistical analyses of its existing trial data, which the FDA classified as a major amendment requiring additional review time. This suggests the FDA needed more data interpretation to support its decision, though it does not indicate a fundamental problem with the application.
Added in current filing · verify on EDGAR →
No new clinical studies were requested, and the FDA did not cite any safety or manufacturing concerns.
The FDA has not asked Praxis to conduct additional clinical trials and has raised no safety or manufacturing issues. This is a positive signal that the core data package and product quality appear acceptable, with the extension focused solely on reviewing the supplemental analyses.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 3, 2026 · How we verify